Kincell Bio produces cell therapies in our GMP manufacturing facilities with the pace early programs demand and the rigor commercialization requires. We utilize standardized platforms wherever possible, reduce manual variability through automated workflows whenever possible, and maintain pre-approval inspection (PAI)-ready facilities every day. This rigor provides the confidence that you can meet rising regulatory expectations and build a resilient supply strategy from Phase I through commercial supply.
Kincell Bio’s two-site manufacturing network supports cell therapy programs from early clinical development through commercialization. Standardized platforms, aligned quality systems, and coordinated processes enable efficient tech transfer between facilities while providing scalable GMP capacity and built-in supply continuity.
Early Development & Clinical Supply
Kincell’s Gainesville facility focuses on early-phase CMC development and clinical manufacturing, helping innovators translate promising science into GMP-ready processes.
Pivotal & Commercial Manufacturing
Our Research Triangle Park facility supports late-stage clinical development and commercial readiness with scalable GMP manufacturing infrastructure.
From the earliest phases of a cell therapy program, we design processes and analytical strategies with clinical and commercial supply at the forefront.
Target Product Profiles and risk-based strategies aligned with IND and long-term commercial goals guide our approach to proof of concept and early-phase clinical manufacturing.
Autologous and allogeneic cell therapies require tailored GMP manufacturing strategies to ensure reproducible, high-quality drug products that meet the program’s needs.
Autologous cell therapy manufacturing follows a one-batch, one-patient model, where success depends on repeatable processes. The focus is on scaling out the ability to produce many patient-specific batches efficiently by reducing manual touchpoints, strengthening chain-of-identity controls, improving in-process analytics, and enabling automation to minimize variability, errors, and turnaround time.
Allogeneic cell therapy manufacturing relies on batch-based scale-up to increase yield and serve more patients per run. Success depends on robust cell banking, scalable expansion platforms, tightly controlled critical process parameters, and process characterization that supports comparability, consistency, and utilization of commercial-ready automation wherever possible.
Kincell Bio brings deep experience across a broad range of autologous and allogenic cell therapy programs, positioning us to support our clients wherever their science leads. Whether supplying preclinical or commercial drug products, we ensure a reliable, high-quality supply.
Kincell provides GMP manufacturing services across the full cell therapy lifecycle, with our Gainesville, FL, USA facility focused on early CMC and clinical supply, and our Research Triangle Park, NC, USA facility emphasizing pivotal and commercial manufacturing. Together, the two facilities provide scalable and redundant GMP capacity, robust analytics, and expansion-ready infrastructure to ensure long-term program continuity and supply reliability.
Kincell Bio develops and delivers tomorrow’s cell therapy cures by integrating comprehensive, end-to-end capabilities across the full product lifecycle, with deep expertise spanning a broad range of autologous and allogeneic cell therapy modalities.
Integrated Services
The Cornerstones of Cell Therapy Excellence, explores analytical, process development, quality, and manufacturing approaches that enable sustainable progress from early development through...
In our new eBook, Navigating Intensifying Cell Therapy Regulatory Expectations, Kincell Bio’s scientific and executive leadership break down what’s changed, why programs...
As allogeneic cell therapies advance toward commercialization, manufacturers must adopt automation and flexible facility designs to improve scalability, consistency, and cost efficiency.
Talk to an expert
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields
